CPHI Online Trend Report: How can flow chemistry help businesses achieve their sustainability goals?
.png)
In our latest CPHI Online Trend Report, we partner with Asymchem to understand the innovative potential of flow chemistry for API manufacturing, especially in regards to meeting sustainability goals.
With insight from industry leaders, academia, and more, this free report gives an in-depth examination of the principles behind flow chemistry, the core tenets of Green Chemistry, and how API manufacturing can maximise the potential of flow technologies in their operations.
Active pharmaceutical ingredients (APIs) form the therapeutic base of almost all drug products. Whether they are small molecule synthetic drugs or biologics derived from human, animal, or microorganism biotechnology, the manufacturing of APIs involves a diverse range of complex chemical and/or biological processes. There are a number of aspects to consider regardless of the type of API, as Jon Brice, Senior Vice President of Business Development at Asymchem Group, comments in the report: “Irrespective of the operational motif, the considerations remain the same – control of impurities, a robust process that can be validated, tracking and quantifying impurities, and collecting data on process parameters.”
Key drivers of API research and manufacturing are in the form of oncology drugs, novel formulations in targeted therapies, and the rise in obesity drugs. One of the most pressing issues for API manufacturers, however, remains balancing sustainability concerns with the safety, quality, and economic viability of their drug products. At each stage of API manufacturing, various solvents, chemicals, and waste products are used and/or produced resulting in a process that is energy and material-intensive. While sustainable operations tend to focus on improving waste reduction, energy efficiency, and greener solvents, there remain untapped opportunities in optimising reaction conditions, reducing the environmental impact of raw materials, and enhancing the overall efficiency of chemical processes, as Senior Scientist at Fraunhofer IMM Gabriele Menges-Flanagan states.
Flow chemistry technologies may be the next transformational technology manufacturers can take advantage of. Such enhancements to operations include improved control over heat and mass transfer, generation and consumption of reactive intermediates in a safer manner, less impurities generated, and improved overall yields. Flow chemistry is also very versatile and flexible with room to be optimised for the reaction taking place. However, some challenges remain for the full adoption of flow technologies in pharmaceutical manufacturing – namely, worker expertise and know-how, as well as regulatory issues around manufacturing practices for flow.
Despite these continuing challenges, experts agree that flow chemistry can offer a number of benefits for API manufacturing, especially in regards to achieving sustainability goals. “You can expand the scope of such a technology, but the real advantage with flow is using it where appropriate and optimising it to a specific problem,” Brice concludes.
To find out more about how flow chemistry can support sustainable API manufacturing, download our FREE Trend Report and gain access to leading industry insight.
Related News
-
News CPHI Americas 2025 - From the Floor
Our From the Floor live blog is back in Philadelphia for this year’s CPHI, this time under the new name CPHI Americas to embrace and represent the whole of the pharmaceutical supply chain from north to south.
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News Welcome back to the CPHI Exhibitor Spotlight!
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.